-

Miravo Healthcare™ Announces Fourth Quarter 2021 Results Release Date and Conference Call Details

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced it expects to release its fourth quarter 2021 financial results before markets open on Monday, March 28, 2022.

The Company will subsequently hold a conference call the same day, Monday, March 28, 2022 at 11:00 a.m. ET, hosted by Jesse Ledger, Miravo’s President & Chief Executive Officer and other senior management. A question-and-answer session will follow the corporate update.

CONFERENCE CALL DETAILS

DATE: Monday, March 28, 2022

TIME: 11:00 a.m. ET

DIAL-IN NUMBERS: (289) 536-4777 or 1 (888) 550-2239

The audio webcast and webcast replay can be accessed at: https://onlinexperiences.com/Launch/QReg/ShowUUID=4A4D2771-F21A-47AB-82F9-727FEDA78FB2

About Miravo Healthcare

Miravo is a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company targets several therapeutic areas, including pain, allergy, neurology and dermatology. The Company’s strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets. Miravo’s head office is located in Mississauga, Ontario, Canada, the international operations are located in Dublin, Ireland and the Company’s manufacturing facility is located in Varennes, Québec, Canada. The Varennes facility operates in a Good Manufacturing Practices (GMP) environment respecting the U.S, Canada and E.U. GMP regulations and is regularly inspected by Health Canada and the U.S. Food and Drug Administration. For additional information, please visit www.miravohealthcare.com.

Contacts

Investor Relations
Stefan Eftychiou
905 326 1888 ext 60
stefan@bristolir.com

Industry:

Nuvo Pharmaceuticals Inc.

TSX:MRV
Release Versions
English

Contacts

Investor Relations
Stefan Eftychiou
905 326 1888 ext 60
stefan@bristolir.com

More News From Nuvo Pharmaceuticals Inc.

Mithra and Searchlight Pharma Sign DONESTA® Licensing Agreement for Canada

LIEGE, Belgium & MONTREAL--(BUSINESS WIRE)--Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, and Searchlight Pharma Inc. (Searchlight), a private Canadian-specialty pharmaceutical company, have signed a License and Supply Agreement for the Canadian rights to DONESTA®, Mithra’s investigational medicine, containing Estetrol, for the treatment of the symptoms of menopause. The signing of the agreement activates a first milestone payout to Mithra of EUR 1.5 million. The two...

Miravo Healthcare Ranks on The Globe and Mail’s Fourth-Annual Women Lead Here Benchmark of Executive Gender Diversity

MISSISSAUGA, Ontario & MONTREAL--(BUSINESS WIRE)--Searchlight Pharma Inc. (“Searchlight”) is pleased to announce that its wholly owned subsidiary, Miravo Healthcare (“Miravo”), has been included on The Globe and Mail’s 2023 Report on Business magazine’s Women Lead Here list. This annual editorial benchmark identifies top-notch Canadian businesses with the highest executive gender diversity. This benchmark was established in 2020 by Report on Business magazine and applies a proprietary research...

Miravo Healthcare™ and Searchlight Pharma Inc. Announce Closing of Arrangement

MISSISSAUGA, Ontario & MONTRÉAL--(BUSINESS WIRE)--Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare (TSX:MRV; OTCQX:MRVFF) (“Miravo” or the “Company”) and Searchlight Pharma Inc., a private Canadian-based specialty healthcare company (“Searchlight”), are pleased to announce the closing of the previously announced plan of arrangement (the “Arrangement”) of Miravo with Searchlight. Under the terms of Arrangement, Searchlight acquired all the issued and outstanding common shares of the Company (th...
Back to Newsroom